Michael Andersson
Overview
Explore the profile of Michael Andersson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
4888
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Buch-Larsen K, Lund-Jacobsen T, Andersson M, Schwarz P
Nutrients
. 2021 Aug;
13(8).
PMID: 34445061
Women with breast cancer are a growing population due to improved screening and treatment. It has been described that chemotherapy can negatively affect patients' metabolism. The aim of this study...
12.
Kolodziejczyk C, Jakobsen M, Jensen M, Bo Poulsen P, Khan H, Kumler T, et al.
Acta Oncol
. 2021 Aug;
60(10):1257-1263.
PMID: 34339355
Background: Only few existing studies have investigated the mortality from cardiovascular disease (CVD) in women with breast cancer (BC). The aim of this study was to investigate CVD mortality in...
13.
Celik A, Berg T, Knoop A, Andersson M
Ugeskr Laeger
. 2021 Jul;
183(26).
PMID: 34219638
Breast cancer is the most common type of cancer among women in Denmark. In 15% of the patients with metastatic breast cancer (mBC) an overexpression of the HER2 protein on...
14.
Marstrand S, Buch-Larsen K, Andersson M, Jensen L, Schwarz P
Cancer Treat Res Commun
. 2021 Jun;
28:100426.
PMID: 34186438
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a recognized adverse effect of standard (neo)adjuvant chemotherapy in breast cancer (BC) treatment. However, there is no consensus on a validated method for assessing...
15.
Buch-Larsen K, Jorgensen N, Jensen L, Andersson M, Schwarz P
Scand J Clin Lab Invest
. 2021 Jun;
81(6):425-431.
PMID: 34120544
Adjuvant treatment for post-menopausal women with early breast cancer (BC) includes aromatase inhibitors (AI), known to decrease bone mineral density (BMD). In this study, we investigate whether denosumab is a...
16.
Soshi T, Andersson M, Kawagoe T, Nishiguchi S, Yamada M, Otsuka Y, et al.
Cereb Cortex
. 2021 May;
31(10):4501-4517.
PMID: 34009242
This study examined exercise intervention effects on older adults' brain structures and function. Brain data were analyzed from 47 healthy adults between 61 and 82 years of age who, in...
17.
Moreno-Aspitia A, Holmes E, Jackisch C, de Azambuja E, Boyle F, Hillman D, et al.
Eur J Cancer
. 2021 Mar;
148:287-296.
PMID: 33765513
Aim: To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial. Patients And Methods: 8381 patients with stage I-III HER2 positive breast cancer randomised to chemotherapy...
18.
Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer M, et al.
J Clin Oncol
. 2021 Feb;
39(13):1448-1457.
PMID: 33539215
Purpose: APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 to 1.00],...
19.
Pedersen J, Strandberg-Larsen K, Andersson M, Hansen J
Occup Environ Med
. 2021 Feb;
78(4):286-292.
PMID: 33531359
Objectives: Previous epidemiological studies have indicated that solar ultraviolet B radiation (UVR) may have a protective effect on breast cancer. However, the evidence remains inconclusive. Despite the fact that outdoor...
20.
Marstrand S, Buch-Larsen K, Andersson M, Jensen L, Schwarz P
Cancer Treat Res Commun
. 2021 Jan;
26:100295.
PMID: 33387870
Background: It is well known that breast cancer (BC) patients often suffer from chemotherapy-induced peripheral neuropathy (CIPN). However, it is not always recognized that they have higher risk of falling,...